Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Eli Lilly's Donanemab Significantly Slowed Cognitive and Functional Decline in Phase 3 Study of Early Alzheimer's Disease
Eli Lilly and Company have announced positive results of the TRAILBLAZER-ALZ 2 Phase 3 study […]
Sosei Heptares and Lilly Enter Multi-target Collaboration and License Agreement in Diabetes and Metabolic Diseases
Sosei Group Corporation announces it has entered a drug discovery collaboration with Eli Lilly and […]
Telix Pharmaceuticals Announces Licence Agreement with Lilly for Olaratumab
Telix Pharmaceuticals Limited (ASX: TLX, “Telix”, the “Company”) today announces that it has entered into […]
US FDA Approves Jardiance ® (empagliflozin) to Treat Adults with Heart Failure Regardless of Left Ventricular Ejection Fraction
The U.S. Food and Drug Administration (FDA) has approved Jardiance ® (empagliflozin) 10 mg to […]
Lilly and Foghorn Announce Strategic Collaboration for Novel Oncology Targets Using Foghorn's Proprietary Gene Traffic Control® Platform
Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Foghorn Therapeutics […]
Lilly Announces Leadership Changes and Formation of Neuroscience and Immunology Business Units
Eli Lilly and Company (NYSE: LLY) today announced executive leadership changes and the creation of neuroscience […]
Lilly and Kumquat Biosciences Announce Collaboration to Discover and Develop Novel Small Molecules that Stimulate Tumor-Specific Immune Responses
Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and […]
Lilly Announces Acquisition of Protomer Technologies
Eli Lilly and Company (NYSE: LLY) today announced the acquisition of Protomer Technologies (“Protomer”), a private […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more